Graves'orbitopathy: current imaging procedures

Graves'orbitopathy: current imaging procedures

Bibliographic Details
Main Authors:	E Kirsch, B Hammer, Arx von
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2009-10-01
Series:	Swiss Medical Weekly
Subjects:	Computed Tomography TIRMsequences magnetic resonance imaging Graves' orbitopathy
Online Access:	https://www.smw.ch/index.php/smw/article/view/1035

Similar Items

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET
by: Anna Ochmann, et al.
Published: (2023-08-01)

Steroid-resistant Graves' orbitopathy: Therapeutic options
by: Klet Sanja, et al.
Published: (2023-01-01)

Dermopathy, Acropachy and Orbitopathy in Graves’ Disease
by: James Young, et al.
Published: (2024-08-01)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
by: Tülay Şimşek, et al.
Published: (2017-01-01)

Role of genetics and epigenetics in Graves’ orbitopathy
by: Michele Marinò, et al.
Published: (2024-11-01)

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
by: Jakub Supronik, et al.
Published: (2022-11-01)

Update on the surgical management of Graves’ orbitopathy
by: Joonyoung Baeg, et al.
Published: (2023-02-01)

Inactive Graves’ orbitopathy: to treat or not to treat?
by: O. G. Panteleeva, et al.
Published: (2023-03-01)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
by: Edelyn Christina, et al.
Published: (2023-06-01)

Color Doppler imaging of the superior ophthalmic vein in patients with Graves' orbitopathy before and after treatment of congestive disease
by: Mário L. R. Monteiro, et al.
Published: (2011-01-01)

Correlation between Structural and Functional Changes in Patients with Raised Intraocular Pressure Due to Graves’ Orbitopathy
by: Freja Bagatin, et al.
Published: (2024-03-01)

Neural Network-Based Pipeline With High-Resolution Feature Enhancement and Low-Resolution Feature Preservation for Automated Treatment Decision of Graves’ Orbitopathy Patients
by: Sanghyuck Lee, et al.
Published: (2024-01-01)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
by: Lilly H. Wagner, et al.
Published: (2022-11-01)

Success Treatment of Severe and Active Graves’ Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone
by: Laurentius Aswin Pramono
Published: (2023-10-01)

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy
by: Diana Bajkowska, et al.
Published: (2022-11-01)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
by: Magdalena Stasiak, et al.
Published: (2023-09-01)

Endoscopic and transcaruncular medial wall decompression in unilateral graves’ orbitopathy: a multicenter randomized study
by: Mahmoud A. El-Samkary, et al.
Published: (2017-07-01)

A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves’ orbitopathy
by: Chiaw-Ling Chng, et al.
Published: (2024-09-01)

ELF3-induced miR-182 inhibits adipogenic differentiation in Graves’ orbitopathy by targeting thyrotropin receptor
by: Sha Wang, et al.
Published: (2023-01-01)

Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study
by: Monika Sarnat-Kucharczyk, et al.
Published: (2022-05-01)

Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves’ Orbitopathy
by: Erika Galgoczi, et al.
Published: (2022-12-01)

Psychiatric complications in Graves’ disease
by: Mats Holmberg, et al.
Published: (2024-02-01)

Steroid Treatment Focused Management of Graves’ Ophthalmopathy
by: Condeng Y. H., et al.
Published: (2024-09-01)

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
by: Gabriela A. Bluszcz, et al.
Published: (2018-12-01)

Imaging studies for diagnosing Graves&#39 orbitopathy and dysthyroid optic neuropathy
by: Allan C. Pieroni Gonçalves, et al.
Published: (2012-11-01)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
by: Joanna Rymuza, et al.
Published: (2022-07-01)

Effectiveness of educational materials on levels of knowledge of thyroid associated orbitopathy in an endocrinology clinic
by: Wajiha J. Kheir, et al.
Published: (2023-12-01)

Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves’ Orbitopathy
by: Yun Yu, et al.
Published: (2024-02-01)

Role of the suppressor of cytokine signaling-3 in the pathogenesis of Graves’ orbitopathy
by: Wonjin Kim, et al.
Published: (2025-03-01)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
by: Michael Oeverhaus, et al.
Published: (2023-04-01)

Efficacy of rituximab in treating steroid-resistant Graves’ orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China
by: Ziyin Zhang, et al.
Published: (2024-06-01)

Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study
by: Maria Novella Maglionico, et al.
Published: (2024-12-01)

Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy
by: Charm Kim, et al.
Published: (2024-08-01)

High IgG4 serum concentration is associated with active Graves orbitopathy
by: Michał Olejarz, et al.
Published: (2023-03-01)

Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves’ orbitopathy
by: Liyun Shen, et al.
Published: (2023-01-01)

Computed tomography and magnetic resonance imaging approaches to Graves’ ophthalmopathy: a narrative review
by: Rafael Luccas, et al.
Published: (2024-01-01)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
by: Jungyul Park, et al.
Published: (2023-05-01)

Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study
by: Rosario Le Moli, et al.
Published: (2024-07-01)

Incidence and risk factors for Graves’ orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves’ disease: investigation of 1,553 cases with newly diagnosed Graves’ disease and proposal of a predictive score
by: Natsuko Watanabe, et al.
Published: (2023-11-01)

The role of hormonal imbalance in the development of autoimmune dacryoadenitis in endocrine orbitopathy
by: V. G. Likhvantseva, et al.
Published: (2014-07-01)